medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2015, Número 3

<< Anterior Siguiente >>

Residente 2015; 10 (3)


Sobre el tratamiento de la enfermedad pulmonar intersticial en artritis reumatoide

Ponce-Campos SD, Martín-Márquez BT, Chávez-García D, Olvera-Palafox CN, Cardona-Müller D, Ponce-Muñoz M, Díaz-Rizo V, González-López L

Idioma: Español
Referencias bibliográficas: 45
Paginas: 132-141
Archivo PDF: 236.90 Kb.


RESUMEN

La artritis reumatoide (AR) es una enfermedad inflamatoria de las articulaciones sinoviales que frecuentemente cursa con manifestaciones sistémicas. La enfermedad pulmonar intersticial (EPI) constituye una de las manifestaciones de esta afectación extraarticular con mayor impacto en la mortalidad. La EPI puede presentarse en servicios clínicos de reumatología afectando alrededor de 3-4% de los pacientes con AR, pero la supervivencia se afecta significativamente sobre todo en individuos con una enfermedad severa; se calcula que la supervivencia puede ser de dos a tres años tras su diagnóstico. Es muy relevante el diagnóstico temprano de esta complicación con el fin de iniciar un tratamiento multidisciplinario. En el establecimiento del diagnóstico, las radiografías de tórax son de baja utilidad en etapas tempranas de la enfermedad, ya que ofrecen una baja sensibilidad y revelan datos anormales sólo en enfermedad severa o etapas tardías. Por ello, deberá considerarse en aquellos sujetos con sospecha de EPI un abordaje diagnóstico integral en el que participen los especialistas de medicina interna, neumología, reumatología y cardiología; este abordaje inicial requiere pruebas de función pulmonar y la tomografía axial computarizada de alta resolución. Esta revisión describe la epidemiología y los factores etiológicos relacionados con el desarrollo de esta entidad; asimismo, se revisan las características clínicas, los métodos de evaluación diagnóstica y la evidencia de los tratamientos utilizados para la EPI, en particular, corticosteroides, inmunosupresores y agentes biológicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86: 3-8.

  2. Norton S, Koduri G, Nokiphorou E, Dixey J, Williams P, Young A. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact outcome. Rheumatology (Oxford). 2013; 52 (1): 99-110.

  3. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011; 183 (3): 372-378.

  4. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev. 2011; 11 (2): 123-131.

  5. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010; 62 (6): 1583-1591.

  6. Habib HM, Eisa AA, Arafat WR, Marie MA. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol. 2011; 30 (2): 217-221.

  7. Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J et al; ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010; 49 (8): 1483-1489.

  8. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008; 168 (2): 159-166.

  9. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012; 106 (11): 1591-1599.

  10. Furukawa H, Oka S, Shimada K; Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, Tsuchiya N, Tohma S. HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis. 2013; 72 (1): 153-155.

  11. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014; 73 (8): 1487-1494.

  12. Yin Y, Liang D, Zhao L, Li Y, Liu W, Ren Y et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One. 2014; 9 (4): e92449.

  13. Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine. 2012; 58 (1): 6-9.

  14. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X; BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011; 124 (5): 386-394.

  15. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004; 71 (4): 301-326.

  16. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002; 165 (2): 277-304.

  17. Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003; 18 (4): 231-236.

  18. Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Hegele R et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001; 164 (2): 193-196.

  19. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly C. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol. 1994; 33 (2): 118-122.

  20. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009; 136 (5): 1397-1405.

  21. Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013; 2013: 406927.

  22. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003; 58 (2): 143-148.

  23. Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int. 2013; 2013: 759760.

  24. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007; 131: (5 Suppl): 4S-42S.

  25. Clark M, Cooper B, Singh S, Cooper M, Carr A, Hubbard R. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax. 2001; 56: 482-486.

  26. Schachna L, Medsger TA Jr, Dauber JH, Wigley FM, Braunstein NA, White B et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006; 54 (12): 3954-3961.

  27. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin. 2012; 8 (2): 68-71.

  28. Cohen JM, Miller A, Spiera H. Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy. Chest. 1977; 72 (4): 521-524.

  29. Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008; 10 (5): R124.

  30. Zhang L, Mo H, Zhu M, Wang L. Effect of cyclophosphamide on cytokines in patients with primary Sjögren’s syndrome-associated interstitial lung disease in South China. Rheumatol Int. 2013; 33 (6): 1403-1407.

  31. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009; 337 (5): 329-335.

  32. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci. 2002; 17 (2): 270-273.

  33. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN et al. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int. 2007; 27 (4): 357-361.

  34. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA Jr. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum. 1985; 28 (8): 882-888.

  35. Wang Y, Xu SQ, Xu JH, Ding C. Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Case Rep. 2011; 4: 49-52.

  36. Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014; 4 (8): e005615.

  37. Matteson EL, Bongartz T, Ryu JH, Crowson CS, Hartman TE, Dellaripa PF. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis. 2012; 2 (3): 53-58.

  38. Becerra E, Cambridge G, Leandro MJ. Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement. Ann Rheum Dis. 2013; 72: A450.

  39. Jiménez-Álvarez L, Arreola JL, Ramírez-Martínez G, Ortiz-Quintero B, Gaxiola M, Reynoso-Robles R et al. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis. Exp Mol Pathol. 2011; 91: 718-722.

  40. Wada T, Akiyama Y, Yokota K, Sato K, Funakubo Y, Mimura T. A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept. Nihon Rinsho Meneki Gakkai Kaishi. 2012; 35 (5): 433-438.

  41. Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P et al; Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014; 16 (4): R144.

  42. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. 2002; 41 (12): 1118-1123.

  43. Mittoo S, Jacob T, Craig A, Bshouty Z. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease. Can Respir J. 2010; 17 (6): 282-286.

  44. Watanabe K, Tajima S, Tanaka J, Moriyama H, Nakayama H, Terada M et al. Effects of anticoagulant therapy for rapidly progressive interstitial pneumonias. Nihon Kokyuki Gakkai Zasshi. 2011; 49 (6): 407-412.

  45. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370 (22): 2093-2101.




2020     |     www.medigraphic.com